US Endometrial Cancer Market

ID: MRFR/MED/15168-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US Endometrial Cancer Market Research Report: Size, Share, Trend Analysis By Types of Treatment (Surgery, Radiation Therapy, Chemotherapy, Hormonal Therapy, Targeted Therapy), By Diagnosis Method (Biopsy, Imaging Tests, Pelvic Exam, Endometrial Sampling), By End Users (Hospitals, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers) and By Stage of Cancer (Early Stage, Locally Advanced Stage, Metastatic Stage) - Growth Outlook & Industry Forecast 2025 To 2035
US Endometrial Cancer Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.63%
2024 Market Size$ 3.84 Billion
2025 Market Size$ 4.08 Billion
2035 Market Size$ 7.02 Billion
Key Players
Merck & Co.
Bristol-Myers Squibb
Pfizer Inc.
AstraZeneca
Genentech
Eli Lilly and Company
Trends
  • Personalized Treatment Approaches
  • Technological Integration in Diagnostics
  • Increased Awareness and Education
Opportunities
  • Government Initiatives and Funding
  • Advancements in Treatment Modalities
  • Growing Focus on Personalized Medicine
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Treatment Type (USD Billion)
      1. 4.1.1 Surgery
      2. 4.1.2 Radiation Therapy
      3. 4.1.3 Chemotherapy
      4. 4.1.4 Hormonal Therapy
    2. 4.2 Healthcare, BY Stage of Cancer (USD Billion)
      1. 4.2.1 Stage I
      2. 4.2.2 Stage II
      3. 4.2.3 Stage III
      4. 4.2.4 Stage IV
    3. 4.3 Healthcare, BY Histological Type (USD Billion)
      1. 4.3.1 Endometrioid Carcinoma
      2. 4.3.2 Serous Carcinoma
      3. 4.3.3 Clear Cell Carcinoma
      4. 4.3.4 Mixed Cell Carcinoma
    4. 4.4 Healthcare, BY Risk Factors (USD Billion)
      1. 4.4.1 Obesity
      2. 4.4.2 Age
      3. 4.4.3 Genetic Mutations
      4. 4.4.4 Hormonal Factors
    5. 4.5 Healthcare, BY Diagnosis Method (USD Billion)
      1. 4.5.1 Ultrasound
      2. 4.5.2 Biopsy
      3. 4.5.3 MRI
      4. 4.5.4 CT Scan
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Merck & Co. (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Pfizer Inc. (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 AstraZeneca (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Genentech (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Eli Lilly and Company (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Novartis (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Amgen Inc. (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Bayer AG (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
    3. 6.3 US MARKET ANALYSIS BY STAGE OF CANCER
    4. 6.4 US MARKET ANALYSIS BY HISTOLOGICAL TYPE
    5. 6.5 US MARKET ANALYSIS BY RISK FACTORS
    6. 6.6 US MARKET ANALYSIS BY DIAGNOSIS METHOD
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
    15. 6.15 HEALTHCARE, BY STAGE OF CANCER, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY STAGE OF CANCER, 2024 TO 2035 (USD Billion)
    17. 6.17 HEALTHCARE, BY HISTOLOGICAL TYPE, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY HISTOLOGICAL TYPE, 2024 TO 2035 (USD Billion)
    19. 6.19 HEALTHCARE, BY RISK FACTORS, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY RISK FACTORS, 2024 TO 2035 (USD Billion)
    21. 6.21 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Billion)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT TYPE, 2026-2035 (USD Billion)
      2. 7.2.2 BY STAGE OF CANCER, 2026-2035 (USD Billion)
      3. 7.2.3 BY HISTOLOGICAL TYPE, 2026-2035 (USD Billion)
      4. 7.2.4 BY RISK FACTORS, 2026-2035 (USD Billion)
      5. 7.2.5 BY DIAGNOSIS METHOD, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Endometrial Cancer Market Segmentation

US Endometrial Cancer Market By Treatment Type (USD Billion, 2026-2035)

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Hormonal Therapy

US Endometrial Cancer Market By Stage of Cancer (USD Billion, 2026-2035)

  • Stage I
  • Stage II
  • Stage III
  • Stage IV

US Endometrial Cancer Market By Histological Type (USD Billion, 2026-2035)

  • Endometrioid Carcinoma
  • Serous Carcinoma
  • Clear Cell Carcinoma
  • Mixed Cell Carcinoma

US Endometrial Cancer Market By Risk Factors (USD Billion, 2026-2035)

  • Obesity
  • Age
  • Genetic Mutations
  • Hormonal Factors

US Endometrial Cancer Market By Diagnosis Method (USD Billion, 2026-2035)

  • Ultrasound
  • Biopsy
  • MRI
  • CT Scan

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.